New York Life Investment Management’s Insulet PODD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.67M Buy
10,973
+1,155
+12% +$192K 0.01% 587
2026
Q1
$2.06M Buy
9,818
+148
+2% +$37.2K 0.02% 537
2025
Q4
$2.75M Buy
9,670
+71
+0.7% +$22.2K 0.02% 455
2025
Q3
$2.96M Buy
9,599
+1
+0% +$313 0.03% 457
2025
Q2
$3.02M Sell
9,598
-7,290
-43% -$2.1M 0.03% 437
2025
Q1
$4.43M Buy
16,888
+34
+0.2% +$9.2K 0.05% 346
2024
Q4
$4.4M Buy
16,854
+7,471
+80% +$1.88M 0.04% 351
2024
Q3
$2.18M Sell
9,383
-299
-3% -$61.4K 0.02% 556
2024
Q2
$1.95M Buy
9,682
+83
+0.9% +$15K 0.02% 559
2024
Q1
$1.65M Sell
9,599
-366
-4% -$68.3K 0.02% 585
2023
Q4
$2.16M Sell
9,965
-70
-0.7% -$12K 0.02% 529
2023
Q3
$1.6M Buy
10,035
+82
+0.8% +$18.4K 0.02% 555
2023
Q2
$2.87M Buy
9,953
+200
+2% +$60.7K 0.03% 428
2023
Q1
$3.11M Buy
+9,753
New +$2.89M 0.03% 412

Other funds holding PODD

New York Life Investment Management's PODD Position: Q2 2026 in Review

New York Life Investment Management increased its Insulet (PODD) stake by 12% in Q2 2026, buying an estimated $192K and bringing the position to 10,973 shares worth $1.67M. The position accounts for 0.01% of the portfolio, ranked #587.

New York Life Investment Management first reported a position in PODD in Q1 2023 and has held it in 14 quarters since. The position peaked at $4.43M in Q1 2025. 522 funds tracked by Wall St. Rank hold PODD as of Q2 2026.

  • New York Life Investment Management held 10,973 shares of Insulet worth $1.67M as of Q2 2026.
  • New York Life Investment Management bought 1,155 Insulet shares in Q2 2026, an estimated $192K.
  • Insulet made up 0.01% of New York Life Investment Management's portfolio in Q2 2026, its #587 holding.
  • New York Life Investment Management first reported a position in Insulet in Q1 2023 and has held it in 14 quarters since.
  • New York Life Investment Management's Insulet position peaked at $4.43M in Q1 2025.
  • 522 funds tracked by Wall St. Rank held Insulet as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.